The Archer® FusionPlex® Lung Kit is a targeted next-generation sequencing (NGS) assay to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The kit is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.
For Research Use Only. Not for use in diagnostic procedures.
# of GSP2s
Input nucleic acid required*
Recommended # of reads
Unique molecular on-target %
Fresh frozen or FFPE
*Input recommendations for FFPE samples vary depending on Archer Preseq® RNA QC score; 50ng input recommended in absence of PreSeq screening
Need to modify your panel?
Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.
Lung cancer is the most deadly form of cancer and the second most-diagnosed cancer in the United States (1). The major types of lung cancer are non-small cell lung cancer and small cell lung cancer.
Lung cancer is estimated to have the highest mortality rate and second highest incidence rate per year in the United States (1).
Non-small cell lung cancer (NSCLC) is much more common than small cell lung cancer, accounting for 85% of all lung cancer cases (2). The survival rate for NSCLC cases varies based on the stage at diagnosis, but the average 5-year survival rate is 15.7% (3). Although NSCLC is often associated with smoking, the subtype is also the most common form in non-smokers and can be attributed to genetic alterations, including single nucleotide polymorphisms (SNPs) and fusion mutations (4, 5).
NSCLC is stratified into 3 subtypes based on phenotypic and genotypic differentiation (2, 6).
Adenocarcinoma is the most common form of NSCLC (40% of lung cancers) (5). Like all lung cancers, this subtype is often linked to smoking, although it is not uncommon for non-smokers to develop this subtype of the disease. Gene fusions associated with NSCLC include but are not limited to ALK, RET, ROS1, FGFR3 and NTRK1. Alternative c-MET splicing leading to exon 14 skipping has also been demonstrated to be oncogenic in adenocarcinomas (7).
Squamous cell carcinoma makes up 25-30% of all lung cancers and is usually linked to smoking (5). FGFR3 mutations have been detected in this NSCLC type (8).
Large cell carcinoma comprises 10-15% of lung cancers (5).
Other types of lung cancer include small cell lung cancer and large carcinoid tumor cancer, making up 10-15% and less than 5% of lung cancers, respectively. They also vary in their rate of progression to metastatic disease, with the former spreading quickly and the latter spreading slowly (5).
The FusionPlex Lung Kit includes primers to detect the following lung cancer-associated targets:
ALK fusions predominate the list of lung cancer-associated fusions. In clinical trials, patients that harbored these fusions displayed greater than 60% radiographic response rate when treated with the tyrosine kinase inhibitor (TKI) crizotinib (9). Also, progression-free survival with crizotinib treatment exceeded that of the standard chemotherapy treatment (7.7 months vs. 3.0 months, respectively) (10). More on ALK, RET & ROS1
RET rearrangements have been reported to convey some level of responsiveness to TKI (cabozantinib) therapy (13). In in vitro models with KIF5B-RET fusions, vandetanib inhibited cell proliferation (14).
In an initial report from a phase II trial with a RET TKI and with prospective RET testing, RET fusion positivity conveyed partial response or disease control with cabozantinib (13, 14). In the clinic, KIF5B-RET fusion-positive lung adenocarcinomas were responsive to vandetanib (15). More on ALK, RET & ROS1
Oncogenic ROS1 rearrangements tend to strike significantly younger patients and is more likely with those who have not smoked (11). In a phase I trial, ROS1-positive NSCLC cases treated with crizotinib exhibited a 72% response rate (12). More on ALK, RET & ROS1
Recent work analyzing 576 adenocarcinomas found the FGFR3-TACC2 fusion in a subset (0.5%) of the samples (8). FGF receptors are currently a popular target in drug discovery and development, and FGFR3 fusions have been suggested for targeting using FGFR inhibitors in clinical trials (8). More on FGFR
A recent study reported that 3 out of 91 (3.3%) of adenocarcinomas carried NTRK1 fusions. In pre-clinical in vitro studies, NTRK1 inhibition causes growth inhibition in a NTRK-fusion positive cell line. In the clinic, crizotinib treatment showed limited efficacy (16). More on NTRK
The c-Met receptor tyrosine kinase is involved in tumorigenesis, cell motility, scattering, invasion and metastasis and has been implicated in small cell lung cancer. Somatic rearrangements have been shown to lead to mutations resulting in the loss of the entire juxtamembrane domain (exon 14) of c-MET (17). More on MET
2477 55th Street, Suite 202
Boulder, CO 80301